Researchers compared trends in the average weekly prescriptions of hydroxychloroquine/chloroquine, azithromycin, and 10 commonly used medications dispensed between February 16 and April 25, 2020 with those dispensed between February 17 and April 27, 2019.
Treatment with remdesivir was associated with a shorter time to recovery in patients hospitalized with coronavirus disease 2019 (COVID-19), according to peer-reviewed data published in the New England Journal of Medicine.
There is a lack of evidence supporting the use of dietary supplements for the prevention or treatment of COVID-19, despite what recent news or social media platforms have asserted,
Sustained improvement was noted after the administration of tocilizumab, an interleukin-6 antagonist.
There is limited evidence supporting the prophylactic use of pharmacological therapies for the prevention of migraine in pediatric patients, according to the findings of a recently published systematic review and network meta-analysis.
Patients with cardiovascular disease diagnosed with novel coronavirus (COVID-19) are urged to continue taking their angiotensin-converting enzyme inhibitor (ACEi) and angiotensin receptor blocker (ARB) medications as prescribed.
Higher doses anti-tumor necrosis factor-α (anti-TNF-α) therapy may be neceessary for obese patients with ulcerative colitis (UC), according to the findings of a recently published meta-analysis.
